Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Tidepool unveils diabetes, women's...
Tech clinical insights

Tidepool unveils diabetes, women's health insights

Analysis based on 12 articles · First reported May 26, 2026 · Last updated Jun 05, 2026

Sentiment
60
Attention
4
Articles
12
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The unveiling of new clinical insights and research initiatives by Tide pool, particularly in diabetes technology and women's health, is likely to positively impact the healthcare and medical device industries. Advancements in diabetes management and data-driven care could lead to improved patient outcomes and potentially drive innovation and investment in related technologies. The collaboration with entities like Oura Health and Stanford University also signals a broader industry effort towards integrated health solutions.

Healthcare Medical Devices Biotechnology
Event Summary

Tide pool, a nonprofit leader in diabetes technology, unveiled new clinical insights and research initiatives at the American Diabetes Association's 86th Scientific Sessions. Key presentations included results from a Diabetes Care Management Program, demonstrating a 1.59% reduction in HbA1c and a 13.4% increase in Time in Range for patients with type 2 diabetes in resource-limited settings. Additionally, Tide pool launched a landmark initiative in women's health research, in collaboration with Diabetes Center Berne, Allen Institute, and Oura Health, aiming to build the largest opt-in, anonymized dataset of biometric and diabetes device data to address underrepresentation in diabetes care. A collaborative study with Stanford University and Replica Health also explored how personalized meal records could improve glycemic control for automated insulin delivery users. Brandon Arbiter, Tide pool's CEO, emphasized the company's commitment to making diabetes data more accessible and actionable.

Key Actions
90 Tide pool unveiled insights, initiatives
90 Diasome Pharmaceuticals announced presentation of results American Diabetes Association
80 Tide pool launched initiative
80 Klara Klein will present data
70 Sushama Reddy shared results
70 Maya Friedman discussed vision
Entities Involved
ngo
Tide pool
Tide pool is the central entity in this event, unveiling new clinical insights and research initiatives in diabetes technology and women's health. This enhances its reputation as an innovator in diabetes management.
Importance 100 Sentiment 70
priv
Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company that developed HDV-Insulin Lispro and will present positive Phase 2b clinical trial results, which could significantly advance its lead insulin program and enhance its market position.
Importance 100 Sentiment 70
ngo
American Diabetes Association
The American Diabetes Association is hosting its 86th Scientific Sessions, providing a platform for Tide pool to present its research and insights, thereby contributing to the advancement of diabetes care.
Importance 70 Sentiment 50
per
Sushama Reddy
Dr. Sushama Reddy, a medical advisor for Tide pool, presented results from a Diabetes Care Management Program, showcasing the effectiveness of data-driven diabetes management.
Importance 40 Sentiment 50
per
Maya Friedman
Maya Friedman, Tide pool's Director of Product Design and User Experience, discussed the company's initiative to address gender equity in diabetes research, aiming to build a large dataset for women's health.
Importance 40 Sentiment 50
per
Kelly Watson
Kelly Watson, Tide pool's Chief Product Officer, commented on the company's roadmap for Tide pool Loop, focusing on reducing the burden of meal logging for people with diabetes.
Importance 30 Sentiment 50
per
Brandon Arbiter
Brandon Arbiter, Tide pool's CEO and Co-founder, emphasized the broader implications of Tide pool's presence at the event, highlighting the company's mission to make a significant impact on the diabetes community.
Importance 30 Sentiment 50
per
Robert Geho
Robert Geho, CEO of Diasome Pharmaceuticals, expressed optimism about the potential of HDV-Insulin Lispro to improve diabetes management.
Importance 30 Sentiment 0
oth
Diabetes Center Berne
Diabetes Center Berne partnered with Tide pool on menstrual cycle research, contributing to the women's health initiative.
Importance 20 Sentiment 40
ngo
Allen Institute
The Allen Institute's Women's Health Network event was the launchpad for Tide pool's landmark initiative in women's health research.
Importance 20 Sentiment 40
priv
Oura Health
Oura Health is collaborating with Tide pool on the women's health initiative, contributing to the collection of biometric and diabetes device data.
Importance 20 Sentiment 40
priv
Replica Health
Replica Health collaborated on a study with Tide pool and Stanford University, evaluating personalized meal records for improved glycemic control in AID users.
Importance 20 Sentiment 40
per
Klara Klein
Klara Klein, a Principal Investigator, will present the OPTI-2 data at the American Diabetes Association's Scientific Sessions.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
HDV-Insulin Lispro is an investigational therapy and has not yet been approved by the United States — Food and Drug Administration.
Importance 10 Sentiment 0
cnt
United States
The OPTI-2 trial was conducted at 27 sites within the United States.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.